

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:

Ruben et al.

Docket No.: PZ003P4

Application No.: 09/852,659

Confirmation No.: 5111

Filed: May 11, 2001

Art Unit: 1636

For: Secreted Protein HPMBQ91 (As Amended)

Examiner: D. Sullivan

SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure imposed by 37 C.F.R. § 1.56 to inform the Patent and Trademark Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of a claim of the subject application, Attorney for Applicants hereby directs the Examiner's attention to references P-Y listed on the attached Form PTO/SB/08. Copies of the references are enclosed.

The listed references are presented so that the Patent and Trademark Office can determine any materiality thereof to the claimed invention. See 37 C.F.R. § 1.104(a) concerning the Examiner's duty to consider and use any such information. Applicants respectfully request that the Examiner make the listed references of record in the file history of the application, and consider the information contained therein during the prosecution of this application.

Identification of the listed references is not to be construed as an admission of any individual associated with the filing or prosecution of the subject application that such references are available as "prior art" against the subject application. Furthermore, Applicants do not waive any rights to take appropriate action to establish patentability over any of the listed documents should they be applied as references against the claims of the subject application.

Pursuant to 37 C.F.R. § 1.97(c), since this Second Supplemental Information Disclosure Statement is being filed after the mailing date of a first Office Action on the merits, but before Application No.: 09/852,659 Docket No.: PZ003P4

the mailing date of a Final Office Action, or a Notice of Allowance under 37 C.F.R. § 1.311, or an action that otherwise closes prosecution, the Patent and Trademark Office will consider this Second Supplemental Information Disclosure Statement if it is accompanied by a statement as specified in 37 C.F.R. § 1.97(e) or the fee as specified in 37 C.F.R. § 1.17(p).

Accordingly, the undersigned certifies pursuant to 37 C.F.R. § 1.97(e)(1) that each item of information contained in this Second Supplemental Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three (3) months prior to the filing of this Second Supplemental Information Disclosure Statement. In particular, the listed references were cited in a European Search Report mailed October 23, 2003, in connection with a corresponding international application.

Applicant believes that no fee is due in connection with this submission. However, should the Patent & Trademark Office determine otherwise, please charge such fee to our Deposit Account No. 08-3425.

Dated: December 1, 2003

Respectfully submitted,

Janet M. Martineau

Régistration No.: 46,903

HUMAN GENOME SCIENCES, INC.

9410 Key West Avenue

Rockville, Maryland 20850

(301) 315-2723

KKH/JMM/FR/ba

DEC 0 1 2003 55

CC TO A NORWITTAL	Complete if Known			
FEE TRANSMITTAL	Application Number	09/852,659-Conf. #5111		
for FY 2004	Filing Date	May 11, 2001		
	First Named Inventor	Steven M. Ruben		
Effective 10/01/2003, Patent fees are subject to annual revision.	Examiner Name	D. Sullivan		
Applicant claims small entity status. See 37 CFR 1.27	Art Unit	1636		
L AMOUNT OF PAYMENT (\$) 0.00	Attorney Docket No.	PZ003P4		
METHOD OF PAYMENT (check all that apply)	FEE CALO	CULATION (continued)		

	Applicant claims small entity status. See 37 CFR 1.27 Art Unit 1636											
TOTAL AMOUNT OF PAYMENT (\$) 0.00						Attom	ey Do	ket No	o. ,	PZ003P4		
ME	THOD	OF PA	YMENT	(check all that	apply)	<u> </u>			FEE	CALCU	LATION (continued)	
Che		Credit	М	oney Oth		3 /	DDITIO	ONAL				
		Card	LJo	derOur	c,] °. ´		J.17.L		'		
X Dep	osit Acco	unt:					e Entity	Small	Entity			
Deposit Account	-		08-342	25		Fee	Fee	Fee	Fee	-	Fan Danasistian	
Number	L					Code	(\$)	Code	(\$)		Fee Description	Fee Paid
Deposit Account	Hum	an Ge	enome S	Sciences, In	c.	1051	130	2051	65	Surcharge	e - late filing fee or oath	
Name The Direct	L			all that apply)		1052	50	2052	25	Surcharge sheet.	e - late provisional filing fee or cover	
	ge fee(s) in			X Credit any	overnavmente	1053	130	1053	130		inh procification	-
				the pendency of						=	ish specification	-
	cation	illona ie	se(s) during	the pendency of	uns	1812	2,520	1812	2,520	_	request for ex parte reexamination	
Char	ge fee(s) ir	dicated	below, exc	ept for the filing	fee	1804	920*	1804	920*	Examiner	ng publication of SIR prior to action	
to the abo	ve-identifi	ed depo	sit accour	nt.		1805	1,840*	1805	1,840*	Requestir Examiner	ng publication of SIR after action	
		FEE (CALCUL	ATION		1251	110	2251	55		for reply within first month	
1. BASI	C FILING	G FEE				1252	420	2252	210	Extension	for reply within second month	F12.1
Large Enti	٠.	II Éntity				1253	950	2253	475	Extension	for reply within third month	* #
Fee Fe		. Fee (\$)	<u>Fee</u>	Description	Fee Paid	1254	1,480	2254	740	Extension	for reply within fourth month	
1001 77		385	Utility fil	ing fee		1255	2,010	2255	1,005	Extension	for reply within fifth month	٠,.
1002 34	0 2002	170	Design	filing fee		1401	330	2401	165	Notice of	Appeal	
1003 53	30 2003	265	Plant fili	ng fee		1402	330	2402	165	Filing a bi	ief in support of an appeal	
1004 77	0 2004	385	Reissue	filing fee		1403	290	2403	145	Request f	or oral hearing	
1005 16	0 2005	80	Provisio	nal filing fee		1451	1,510	1451	1,510	Petition to	institute a public use proceeding	
		SUR	TOTAL ((1) (\$)	0.00	1452	110	2452	55	Petition to	revive – unavoidable	
		000	TOTAL (Ψ, (Ψ)	0.00	1453	1,330	2453	665	Petition to	revive - unintentional	
2. EXTR	A CLAII	M FEE		UTILITY AND	REISSUE	1501	1,330	2501	665	Utility issu	ue fee (or reissue)	
i			Extra Claims	Fee from below	Fee Paid	1502	480	2502	240	Design is:	sue fee	
Total Claim	ıs	-20**		x	=	1503	640	2503	320	Plant issu	e fee	
Independer Claims	nt T	-3**		× =	=	1460	130	1460	130	Petitions 1	to the Commissioner	
Multiple De	pendent	•		·	-	1807	50	1807	50	Processin	g fee under 37 CFR 1.17(q)	
Large Enti	ty Small	Entity				1806	180	1806	180	Submissi	on of Information Disclosure Stmt	
Fee Fe Code (\$	e Fee	Fee (\$)	-	Fee Description	<u>on</u>	8021	40	8021	40		geach patent assignment per times number of properties)	
1202 18	´	9	Claims in	excess of 20		1809	770	2809	385	Filing a st	ubmission after final rejection	
1201 86	2201	43	Independe	ent claims in exc	ess of 3					(37 CFR	1.129(a)) additional invention to be	
1203 29	-		•	ependent claim,	•	1810	770	2810	385	examined	(37CFR 1.129(b))	
1204 86	2204	43		e independent cla ginal patent	aims	1801	770	2801	385		or Continued Examination (RCE) or expedited examination	<u> </u>
1205 18	2205	9	** Reissue	claims in exces		1802	900	1802	900		n application	
1			and ove	er original patent		Other	fee (spe	cify)				
1			BTOTAL		0.00	*Redu	iced by E	Basic Fi	ling Fee	Paid	SUBTOTAL (3) (\$)	0.00
**or numb	er previou	sly paid	d, if greate	r, For Reissues,	see above							
SUBMITTE	D BV										(Complete (if applicable))	_

SUBMITTED BY			(Complete	(п аррисавіе))
Name (Print/Type)	Janet M. Martineau	Registration No. (Attorney/Agent)	6,903 Telephone	(301) 315-2723
Signature	(Muth)	Mark	Date	December 1, 2003
		7		•



Sheet

PTO/SB/08a/b (06-03)
Approved for use through 07/31/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO

1

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

of

2

(oce as many onesis as necessary)

Complete if Kn wn				
Application Number	09/852,659-Conf. #5111			
Filing Date	May 11, 2001			
First Named Inventor	Steven M. Ruben			
Art Unit	1636			
Examiner Name	D. Sullivan			
Attorney Docket Number	PZ003P4			

	U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	

	FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
	Р	EP-0 892 053-A2		SmithKline Beecham PLC and Human Genome Sciences, Inc.		
	Q	WO-98/55612-A1		Zymogenetics, Inc.		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. There office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R	BONNER et al., "A cDNA encoding the precursor of the rat neuropeptide, neurokinin B," <i>Molec. Brain Res.</i> , 2(3):243-249 (1987).	
	S	KAKO et al., "Cloning and Sequence Analysis of Mouse cDNAs Encoding Preprotachykinin A and B," <i>Biomed. Res.</i> , 14(4):253-259 (1993).	
	Т	EBI Accession No. AA004764, HILLIER et al., "zh89a10.r1 Soares fetal liver spleen 1NFLS S1 Homo sapiens cDNA clone 428442 5' similar to SW:TKNK_BOVIN P08858 NEUROKININ B PRECURSOR, mRNA sequence" (Jul. 25, 1996).	
	U	EBI Accession No. T54351, HILLIER et al., "ya93h08.s1 Stratagene placenta (#937225) Homo sapiens cDNA clone IMAGE:69279 3' similar to SP:TKNK_BOVIN P08858 NEUROKININ B PRECURSOR, mRNA sequence" (Feb. 28, 1995).	
	V	EBI Accession No. R63635, HILLIER et al., "yi09f09.r1 Soares placenta Nb2HP Homo sapiens cDNA clone IMAGE:138761 5' similar to SP:TKNK_BOVINE P08858 NEUROKININ B PRECURSOR, mRNA sequence" (May 31, 1995).	
	W	EBI Accession No. T58582, HILLIER et al., "ya93h08.r1 Stratagene placenta (#937225) Homo sapiens cDNA clone IMAGE:69279 5' similar to SP:TKNK_BOVIN P08858 NEUROKININ B PRECURSOR, mRNA sequence" (Mar. 4, 1995).	

Examiner Date Signature			
Signature	xaminer	 Date	
Sidilature Considered	Signature	Considered	



PTO/SB/08a/b (06-03)
Approved for use through 07/31/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE sound to a collection of information unless it contains a valid OMB control number.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 2 of 2

	Complete if Known				
Application Number	09/852,659-Conf. #5111				
Filing Date	May 11, 2001				
First Named Inventor	Steven M. Ruben				
Art Unit	1636				
Examiner Name	D. Sullivan				
Attorney Docket Number	PZ003P4				

	EBI Accession No. R62763, HILLIER et al., "yi10c09.r1 Soares placenta Nb2HP Homo sapiens cDNA clone IMAGE:138832 5' similar to SP:TKNK_BOVIN P08858 NEUROKININ B PRECURSOR, mRNA sequence" (May 30, 1995).	
Υ	LANG et al., "Neurochemical characterization of preprotachykinin B(50-79) immunoreactivity in the rat," <i>Regulatory Peptides</i> , 57:183-192 (1995).	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.